Neovascular Age-Related Macular Degeneration
VA, OCT necessary for nAMD management, researchers calls for improved guidelines
A review of guidelines for neovascular age-related macular degeneration shows a high level of agreement on the use of optical coherence tomography and visual acuity in diagnosis and monitoring.
nAMD and DME: Novel Treatment Plans to Prioritize Real-World Visual Improvements
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Avacincaptad pegol may help preserve driving eligibility in patients with GA
Avacincaptad pegol may help postpone driving restrictions or loss of driving eligibility in patients with geographic atrophy, according to a post hoc analysis of the GATHER1 and GATHER2 trials.
Study examines characteristics of vision loss after subretinal hemorrhage in wet AMD
Patients with neovascular age-related macular degeneration who experienced catastrophic vision loss after subretinal hemorrhage were linked to longer anti-VEGF treatment duration and shorter time from prior injection.
Geographic Atrophy Secondary to Age-Related Macular Degeneration: Innovative Therapies for Sight Revival
This activity is supported by educational grants from Apellis Pharmaceuticals, Inc., and Topcon Healthcare, Inc.
The Retina Radar With Dr. Arshad Khanani on CTS, nAMD, DME, and Sustained Delivery
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc.; Genentech, a member of the Roche Group; AbbVie Inc.; Astellas; Apellis Pharmaceuticals, Inc.; Opthea; Alimera Sciences, Inc.; EyePoint Pharmaceuticals, Inc.; Neurotech Pharmaceuticals, Inc.; REGENXBIO Inc.; and Ocular Therapeutix, Inc.
Participant visits complete in phase 2b trial of CLS-AX for wet AMD
Clearside Biomedical announced the completion of the final participant visit in its ODYSSEY phase 2b clinical trial of CLS-AX, an axitinib injectable suspension for neovascular age-related macular degeneration.
Good outcomes seen 9 months after switching to faricimab for wet AMD treatment
Eyes with neovascular age-related macular degeneration that switched to faricimab generally had lower rates of lesion activity, longer treatment intervals and stable visual acuity.
VIDEO: Safety data encouraging for 4D-150 in patients with wet AMD
In this video, Donald J. D’Amico, MD, discusses data from the phase 1/2 PRISM trial of 4D-150 in patients with neovascular age-related macular degeneration.
‘Don’t give up’: Persistent treatment with faricimab shows promise for delayed responders
Patients with neovascular age-related macular degeneration who have responded poorly to anti-VEGF monotherapy may require an average of nine injections of faricimab before improvement is seen.